Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat.
about
Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signalingEverolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.Nestin expression in repopulating mesangial cells promotes their proliferation.PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis.Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient.Induction monotherapy with sirolimus has selected beneficial effects on glomerular and tubulointersititial injury in nephrotoxic serum nephritis.Transgelin is a marker of repopulating mesangial cells after injury and promotes their proliferation and migration.The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response.Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Differential effects of rapamycin in anti-GBM glomerulonephritis.Is There a Role for Mammalian Target of Rapamycin Inhibition in Renal Failure due to Mesangioproliferative Nephrotic Syndrome?Rapamycin ameliorates proteinuria and restores nephrin and podocin expression in experimental membranous nephropathy.Effects of everolimus on cytokines, oxidative stress, and renal histology in ischemia-reperfusion injury of the kidney.Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.Rapamycin-induced proteinuria following allogeneic hematopoietic stem cell transplantation.Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.Everolimus-induced tubular toxicity in non-renal cancer.Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production.Everolimus-induced loss of wound strength can be prevented by a short postoperative delay in its administrationRecent Progress in the Pathogenesis of Nephrotic ProteinuriaThe podocyte as a direct target of immunosuppressive agents
P2860
Q27315815-B04D6D10-B557-4D93-BD81-3F91EBD0D851Q33251433-42901388-0A05-422C-89F1-D9E11487DDB0Q33319371-11E542DD-04E7-4FB6-99B2-45FCB4FCD1E8Q33348441-8B4544D9-9C78-4F90-847B-1DFBB4FD1643Q33389749-B25DC752-3508-43EF-AF89-563546127733Q33952749-96F55A1D-5861-4D6D-8D6D-69A92CA7FB95Q34217138-7902ED7E-1FDB-4846-819F-6B757F5BA5BEQ34303766-E8DA245E-E229-4A9E-B54C-D4BCA437C3F2Q34695551-5A5B1BCD-66FD-4710-A19E-720580FA280FQ37760379-611D6EB8-5F05-4DA4-881E-C78B93E62322Q38914374-8CD9EF45-43E0-4D30-836A-9AA2A6D414C0Q41066466-942AB00F-D808-47D7-964E-E977FF92BA79Q41787297-F3966ED8-A055-4349-8DCF-375B469C73F9Q41854722-5C6E070A-D21D-475D-A216-94E966414A1CQ43265105-9F2CB591-4FAD-483A-888C-B5F846157454Q43293883-0777F698-82EB-4D62-B867-C65A513B1CF2Q44779498-5DDEEB12-976D-46AB-B368-605E9EDC645BQ46158153-8EF27B3C-EA14-4D11-966B-046B789B4F77Q46840790-874CA365-85D2-49B3-AC4B-8FE60FBA2DF2Q52941879-8DB08D51-5137-4AD0-9A94-0F06D9D1C17BQ54588250-F84AB685-1F42-48F1-A5D5-64961CDB8928Q57119713-2822702C-8ACC-4A85-8F08-4EC3BF952564Q57825276-8B846DD9-6556-475C-974F-93FD866A470BQ58177753-41920733-74CB-40DC-8ABA-77A98D148C7D
P2860
Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat.
@ast
Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat.
@en
type
label
Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat.
@ast
Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat.
@en
prefLabel
Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat.
@ast
Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat.
@en
P2093
P2860
P1476
Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat
@en
P2093
P2860
P304
P356
10.1111/J.1600-6143.2005.01120.X
P407
P577
2005-12-01T00:00:00Z